Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

ConferenceHWK-007Positive

AI Analysis

Summary

Whitehawk Therapeutics presented real-world analyses at WCLC 2026 demonstrating PTK7 expression stability after standard-of-care therapies in EGFR wild-type NSCLC, supporting the development of its PTK7-directed ADC HWK-007 in Phase 1.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Real-world analyses presented at WCLC 2026 supporting PTK7 as a durable ADC target

Importance:5/10

Sentiment:

0.60

ADCPTK7 targetNSCLCreal-world dataconference presentation

Related Companies

$GBIO $CBDY $WHEN

Read the original article

Published by PR Newswire Biotech on September 14, 2026 1:30 AM

Read Original